These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 30553760)

  • 21. Do Tau Deposition and Glucose Metabolism Dissociate in Alzheimer's Disease Trajectory?
    Nowell J; Raza S; Livingston NR; Sivanathan S; Gentleman S; Edison P
    J Alzheimers Dis; 2024; 101(3):987-999. PubMed ID: 39302365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of plasma glucose level on the pattern of brain FDG uptake and the predictive power of FDG PET in mild cognitive impairment.
    Apostolova I; Lange C; Suppa P; Spies L; Klutmann S; Adam G; Grothe MJ; Buchert R;
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1417-1422. PubMed ID: 29502311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study.
    Inui Y; Ito K; Kato T;
    J Alzheimers Dis; 2017; 60(3):877-887. PubMed ID: 28922157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnestic MCI.
    Tripathi M; Tripathi M; Parida GK; Kumar R; Dwivedi S; Nehra A; Bal C
    Neurol India; 2019; 67(5):1310-1317. PubMed ID: 31744965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regression.
    Teipel SJ; Kurth J; Krause B; Grothe MJ;
    Neuroimage Clin; 2015; 8():583-93. PubMed ID: 26199870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arterial spin labeling versus
    Dolui S; Li Z; Nasrallah IM; Detre JA; Wolk DA
    Neuroimage Clin; 2020; 25():102146. PubMed ID: 31931403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects.
    Ewers M; Brendel M; Rizk-Jackson A; Rominger A; Bartenstein P; Schuff N; Weiner MW;
    Neuroimage Clin; 2014; 4():45-52. PubMed ID: 24286024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Limbic Network Derangement Mediates Unawareness of Apathy in Mild Cognitive Impairment due to Alzheimer's Disease: Clues from [18F]FDG PET Voxel-Wise Analysis.
    Kreshpa W; Raffa S; Girtler N; Brugnolo A; Mattioli P; Orso B; Calizzano F; Arnaldi D; Peira E; Chincarini A; Tagliafico L; Monacelli F; Calcagno P; Serafini G; Gotta F; Mandich P; Pretta S; Del Sette M; Sofia L; Sambuceti G; Morbelli S; Schenone A; Massa F; Pardini M;
    J Alzheimers Dis; 2024; 101(2):475-485. PubMed ID: 39240639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individual brain metabolic connectome indicator based on Kullback-Leibler Divergence Similarity Estimation predicts progression from mild cognitive impairment to Alzheimer's dementia.
    Wang M; Jiang J; Yan Z; Alberts I; Ge J; Zhang H; Zuo C; Yu J; Rominger A; Shi K;
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2753-2764. PubMed ID: 32318784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer's Disease in Subjects with Mild Cognitive Impairment.
    Garibotto V; Trombella S; Antelmi L; Bosco P; Redolfi A; Tabouret-Viaud C; Rager O; Gold G; Giannakopoulos P; Morbelli S; Nobili F; Perneczky R; Didic M; Guedj E; Drzezga A; Ossenkoppele R; Berckel BV; Ratib O; Frisoni GB
    Curr Alzheimer Res; 2020; 17(13):1186-1194. PubMed ID: 33583380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia.
    Cerami C; Della Rosa PA; Magnani G; Santangelo R; Marcone A; Cappa SF; Perani D
    Neuroimage Clin; 2015; 7():187-94. PubMed ID: 25610780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment.
    Wu L; Rowley J; Mohades S; Leuzy A; Dauar MT; Shin M; Fonov V; Jia J; Gauthier S; Rosa-Neto P;
    PLoS One; 2012; 7(10):e47905. PubMed ID: 23112868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes.
    Blazhenets G; Frings L; Sörensen A; Meyer PT;
    J Nucl Med; 2021 Jun; 62(6):855-860. PubMed ID: 33097630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.
    Mosconi L; Perani D; Sorbi S; Herholz K; Nacmias B; Holthoff V; Salmon E; Baron JC; De Cristofaro MT; Padovani A; Borroni B; Franceschi M; Bracco L; Pupi A
    Neurology; 2004 Dec; 63(12):2332-40. PubMed ID: 15623696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study.
    Pagani M; De Carli F; Morbelli S; Öberg J; Chincarini A; Frisoni GB; Galluzzi S; Perneczky R; Drzezga A; van Berckel BN; Ossenkoppele R; Didic M; Guedj E; Brugnolo A; Picco A; Arnaldi D; Ferrara M; Buschiazzo A; Sambuceti G; Nobili F
    Neuroimage Clin; 2015; 7():34-42. PubMed ID: 25610765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid biomarkers as predictors of conversion from mild cognitive impairment to Alzheimer's dementia: a comparison of methods.
    Sörensen A; Blazhenets G; Schiller F; Meyer PT; Frings L;
    Alzheimers Res Ther; 2020 Nov; 12(1):155. PubMed ID: 33213489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct subtypes of spatial brain metabolism patterns in Alzheimer's disease identified by deep learning-based FDG PET clusters.
    Ryoo HG; Choi H; Shi K; Rominger A; Lee DY; Lee DS;
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):443-454. PubMed ID: 37735259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alzheimer Disease and Mild Cognitive Impairment: Integrated Pulsed Arterial Spin-Labeling MRI and
    Riederer I; Bohn KP; Preibisch C; Wiedemann E; Zimmer C; Alexopoulos P; Förster S
    Radiology; 2018 Jul; 288(1):198-206. PubMed ID: 29762090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.